# Keynote Case Study: Pfizer — Healthcare Was Entering an Era of Exponential Science
By 

## Article Content
Healthcare was changing faster than at almost any point in modern history. That was the message I brought to Pfizer's global team in Paris. The keynote focused on the acceleration of healthcare. Genomic science was evolving rapidly. Gene therapy was advancing. Medical knowledge was expanding. Connected devices were beginning to virtualize parts of the healthcare experience. And the relationship between patient and physician was changing as people gained access to more information, more tools and more insight into their own health. The important point was not any one technology. It was the rate at which all of them were advancing together. Healthcare has traditionally been built around long development cycles, complex regulation and cautious adoption. Those realities remain. But the science surrounding the system is moving much faster. That creates tension. The knowledge base accelerates. The technology improves. Patients become more informed. New therapies emerge. Yet the institutions responsible for delivering care often move on a much slower clock. Six themes framed the discussion: Genomic Acceleration. Genetic science was becoming central to the future of diagnosis, treatment and prevention. Gene Therapy. New therapeutic approaches were expanding the boundaries of what medicine might be able to treat. Virtualized Healthcare. Connected medical devices were allowing more care and monitoring to move beyond traditional facilities. Medical Knowledge Explosion. The volume of scientific insight was growing faster than conventional professional knowledge systems. Changing Patient Relationships. Patients were becoming more informed, connected and active participants in healthcare decisions. Exponential Science. The cumulative effect of accelerating science was creating more change than healthcare had experienced in generations. The larger strategic challenge was one of timing. Scientific possibility can move ahead of institutional readiness. That means leaders need to understand not just what is possible today, but what is becoming possible next. In pharmaceuticals, that affects research. Development. Clinical strategy. Partnerships. Data. And the way organizations think about the patient journey. My message to the Pfizer audience was that healthcare was entering a fundamentally different era. Not simply because new discoveries were happening. But because the rate of discovery itself was accelerating. The future of healthcare would increasingly be defined by organizations capable of moving with exponential science.

---
Source: https://jimcarroll.com/2019/07/keynote-case-study-pfizer-healthcare-was-entering-an-era-of-exponential-science/